These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38811083)

  • 61. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis.
    Sipe JD; Benson MD; Buxbaum JN; Ikeda S; Merlini G; Saraiva MJ; Westermark P
    Amyloid; 2010 Sep; 17(3-4):101-4. PubMed ID: 21039326
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils.
    Ren R; Hong Z; Gong H; Laporte K; Skinner M; Seldin DC; Costello CE; Connors LH; Trinkaus-Randall V
    J Biol Chem; 2010 Nov; 285(48):37672-82. PubMed ID: 20870723
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Amyloidosis-associated kidney disease.
    Dember LM
    J Am Soc Nephrol; 2006 Dec; 17(12):3458-71. PubMed ID: 17093068
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pathology of amyloidosis and amyloid heart disease.
    Lie JT
    Appl Pathol; 1984; 2(6):341-56. PubMed ID: 6400465
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amyloid fibril proteins.
    Xing Y; Higuchi K
    Mech Ageing Dev; 2002 Nov; 123(12):1625-36. PubMed ID: 12470900
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Amyloid Oligomers, Protofibrils and Fibrils.
    Siddiqi MK; Majid N; Malik S; Alam P; Khan RH
    Subcell Biochem; 2019; 93():471-503. PubMed ID: 31939162
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Renal amyloidosis (part I).
    Ferrario F; Rastaldi MP
    J Nephrol; 2006; 19(2):123-5. PubMed ID: 16736407
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Mucocutaneous manifestations of amyloidosis].
    Timmer-de Mik L; van der Waal RI; Canninga-van Dijk MR; Dikland WJ; Rodenburg CJ; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2007 Sep; 151(37):2032-8. PubMed ID: 17929711
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee.
    Buxbaum JN; Dispenzieri A; Eisenberg DS; Fändrich M; Merlini G; Saraiva MJM; Sekijima Y; Westermark P
    Amyloid; 2022 Dec; 29(4):213-219. PubMed ID: 36420821
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [From amyloid proteins to amyloidosis].
    Delpech M
    Rev Prat; 1997 Oct; 47(16):1761-6. PubMed ID: 9453199
    [TBL] [Abstract][Full Text] [Related]  

  • 71. AA amyloid fibrils from diseased tissue are structurally different from in vitro formed SAA fibrils.
    Bansal A; Schmidt M; Rennegarbe M; Haupt C; Liberta F; Stecher S; Puscalau-Girtu I; Biedermann A; Fändrich M
    Nat Commun; 2021 Feb; 12(1):1013. PubMed ID: 33579941
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Significance of Oligomeric and Fibrillar Species in Amyloidosis: Insights into Pathophysiology and Treatment.
    Koike H; Iguchi Y; Sahashi K; Katsuno M
    Molecules; 2021 Aug; 26(16):. PubMed ID: 34443678
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer's disease and other diseases with amyloid deposits.
    Stefani M
    Prog Neurobiol; 2012 Dec; 99(3):226-45. PubMed ID: 22450705
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Human lysozyme inhibits the fibrillation of serum amyloid a protein from systemic AA amyloidosis.
    Moderer T; Puşcalău-Gîrţu I; Haupt C; Baur J; Rodríguez-Alfonso A; Wiese S; Schmidt CQ; Malešević M; Forssmann WG; Ständker L; Fändrich M
    Amyloid; 2023 Dec; 30(4):424-433. PubMed ID: 37431668
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential effects on light chain amyloid formation depend on mutations and type of glycosaminoglycans.
    Blancas-Mejía LM; Hammernik J; Marin-Argany M; Ramirez-Alvarado M
    J Biol Chem; 2015 Feb; 290(8):4953-4965. PubMed ID: 25538238
    [TBL] [Abstract][Full Text] [Related]  

  • 76. β-Barrels and Amyloids: Structural Transitions, Biological Functions, and Pathogenesis.
    Sulatskaya AI; Kosolapova AO; Bobylev AG; Belousov MV; Antonets KS; Sulatsky MI; Kuznetsova IM; Turoverov KK; Stepanenko OV; Nizhnikov AA
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768745
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates.
    Khurana R; Gillespie JR; Talapatra A; Minert LJ; Ionescu-Zanetti C; Millett I; Fink AL
    Biochemistry; 2001 Mar; 40(12):3525-35. PubMed ID: 11297418
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Al amyloidosis.
    Desport E; Bridoux F; Sirac C; Delbes S; Bender S; Fernandez B; Quellard N; Lacombe C; Goujon JM; Lavergne D; Abraham J; Touchard G; Fermand JP; Jaccard A;
    Orphanet J Rare Dis; 2012 Aug; 7():54. PubMed ID: 22909024
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intermediate amyloid oligomers of lysozyme: Is their cytotoxicity a particular case or general rule for amyloid?
    Malisauskas M; Darinskas A; Zamotin VV; Gharibyan A; Kostanyan IA; Morozova-Roche LA
    Biochemistry (Mosc); 2006 May; 71(5):505-12. PubMed ID: 16732728
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Portal amyloid: novel amyloid deposits in gastrointestinal veins?
    Rocken C; Saeger W; Linke RR
    Arch Pathol Lab Med; 1996 Nov; 120(11):1044-51. PubMed ID: 12049107
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.